Prognostic Stratification of Bladder Cancer Patients with a MicroRNA-based Approach.
bladder cancer
liquid biopsy
microRNAs
prognostic stratification
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Oct 2020
26 Oct 2020
Historique:
received:
01
10
2020
revised:
20
10
2020
accepted:
21
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
Robust non-invasive tests for prognostic stratification of bladder cancer (BCa) patients are in high demand. Following a comprehensive analysis of studies on BCa, we selected a panel of 29 microRNAs (miRNAs) and analyzed their levels in urine and plasma samples in a prospective cohort of 63 BCa patients (32 at high risk of recurrence and 31 low-risk cases) and 37 healthy controls using RT-qPCR. To design an assay suitable for large-scale testing, we applied a hierarchical pipeline to select the miRNAs that were not affected by confounding factors such as haematuria and urine specific gravity, and exceeded stringent cut-off criteria (fold change >2.5 and
Identifiants
pubmed: 33114775
pii: cancers12113133
doi: 10.3390/cancers12113133
pmc: PMC7692037
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Istituto Oncologico Veneto
ID : 5x1000
Organisme : University of Padova
ID : SID16_01 and BIRD 205490
Références
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
J Mol Diagn. 2016 Jan;18(1):15-22
pubmed: 26586227
J Surg Oncol. 2015 Jun;111(8):992-9
pubmed: 25975233
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3713-8
pubmed: 21300873
Int J Mol Sci. 2018 Aug 24;19(9):
pubmed: 30149597
Int J Mol Sci. 2017 Oct 02;18(10):
pubmed: 29036883
Int J Mol Cell Med. 2015 Winter;4(1):32-9
pubmed: 25815280
Ann Surg. 2014 Apr;259(4):735-43
pubmed: 23982750
Cell Death Dis. 2017 Oct 12;8(10):e3100
pubmed: 29022903
J Cancer. 2016 Aug 7;7(12):1740-1746
pubmed: 27698912
Oncol Lett. 2019 Nov;18(5):5549-5554
pubmed: 31612063
Biomed Res Int. 2017;2017:1928021
pubmed: 28321402
Urol Oncol. 2010 Nov-Dec;28(6):655-61
pubmed: 19375957
J Exp Clin Cancer Res. 2016 Nov 7;35(1):173
pubmed: 27821145
Biomark Med. 2018 Jun;12(6):667-676
pubmed: 29896971
Int J Mol Sci. 2020 May 27;21(11):
pubmed: 32471285
J Exp Clin Cancer Res. 2014 Dec 31;33:779
pubmed: 25551284
Dis Markers. 2018 Jul 4;2018:6071826
pubmed: 30069274
Br J Cancer. 2016 Feb 16;114(4):454-62
pubmed: 26812572
Clin Genitourin Cancer. 2012 Jun;10(2):106-13
pubmed: 22386240
Exp Ther Med. 2017 Jul;14(1):10-17
pubmed: 28672887
Int J Cancer. 2009 May 1;124(9):2236-42
pubmed: 19127597
Mol Cancer. 2014 Jan 15;13:8
pubmed: 24423412
Int J Cancer. 2019 Jan 15;144(2):380-388
pubmed: 30183088
PLoS One. 2011;6(9):e24145
pubmed: 21909417
Br J Cancer. 2012 Jun 26;107(1):123-8
pubmed: 22644299
Cancer Res. 2009 Nov 1;69(21):8472-81
pubmed: 19843843
Methods Mol Biol. 2017;1660:111-130
pubmed: 28828652
Int J Cancer. 2018 Jun 15;142(12):2501-2511
pubmed: 29388209
Br J Cancer. 2016 Jun 14;114(12):1362-6
pubmed: 27228285
Cancer Sci. 2011 Mar;102(3):522-9
pubmed: 21166959
J Transl Med. 2020 Feb 3;18(1):51
pubmed: 32014049
Oncotarget. 2017 Jun 20;8(25):40832-40842
pubmed: 28388561
Oncotarget. 2015 Dec 8;6(39):42258-75
pubmed: 26517683
Front Oncol. 2018 Sep 07;8:362
pubmed: 30245975
Cancer Res. 2009 Jun 1;69(11):4851-60
pubmed: 19487295
Int J Cancer. 2017 Jan 1;140(1):176-187
pubmed: 27632639
Oncol Lett. 2018 Oct;16(4):4114-4128
pubmed: 30250529
Mol Biol Cell. 2011 May 15;22(10):1686-98
pubmed: 21411626
Cell Physiol Biochem. 2018;48(1):87-98
pubmed: 30001529
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
Carcinogenesis. 2012 Apr;33(4):828-34
pubmed: 22298638